Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2023-02-01 Call Transcript
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a letter dated February 1, 2023, addressed to stock exchanges regarding the schedule of an investor conference call for Jubilant Pharmova Limited. It announces the rescheduling of the conference call for discussing the unaudited financial results for the quarter ended December 31, 2022. The document includes details about the conference call timing, dial-in numbers, and registration instructions. It does not contain actual financial statements or detailed financial analysis but is an announcement about the timing and logistics of the conference call where such information will be discussed. Therefore, this document is best classified as a Call Transcript announcement or schedule update, but since it is only the schedule notice and not the transcript itself, it fits under the category of Call Transcript (CT) as it relates to the conference call event. Confidence is high as the document clearly focuses on the conference call schedule for quarterly financial results discussion.
2023-02-01 English
Updates
Regulatory Filings Classification · 95% confidence The document is a press release dated January 31, 2023, announcing that Jubilant Pharmova Limited's subsidiary received US FDA approval for a new drug application (NDA) for Technetium Mertiatide Injection. It is addressed to stock exchanges and is intended for information and records. The content focuses on the announcement of regulatory approval and business information rather than detailed financial data or comprehensive reporting. There are no financial statements, management discussion, or detailed report content. The document is a communication of a significant business event (FDA approval) via a press release, which fits best under a Regulatory Filings (RNS) category as a general regulatory announcement. It is not an Annual Report, Earnings Release, or any other specific report type. The document length is moderate (6827 characters), but the content is clearly an announcement, not a full report or transcript.
2023-01-31 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notice from Jubilant Pharmova Limited announcing the schedule of an investor conference call to discuss the unaudited financial results for the quarter and nine months ended December 31, 2022. It includes details about the conference call timing, dial-in numbers, and registration instructions. There is no actual financial data or detailed financial analysis included in the document. The document is essentially an announcement of a conference call event related to financial results, not the transcript or the financial report itself. Therefore, it fits the category of a Call Transcript (CT) only if it contained the full transcript, but since it is only a schedule announcement, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a regulatory announcement pursuant to SEBI regulations about an upcoming conference call. The document length is 5638 characters, which is not very short, but the content is clearly an announcement, not the report or transcript itself. Hence, the best classification is Regulatory Filings (RNS).
2023-01-27 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a short notice informing the stock exchanges about an upcoming Board Meeting scheduled for February 3, 2023. The purpose of the meeting is to consider unaudited financial results for the quarter and nine months ended December 31, 2022. The document references Regulation 29 of the SEBI Listing Regulations, which governs disclosures related to board meetings. The document does not contain any financial data or results itself, nor does it attach or publish any report. It is an announcement of a board meeting, not the meeting materials or results. Therefore, it fits best under the category of Board/Management Information (MANG), which includes announcements of board meetings and related disclosures.
2023-01-25 English
Updates
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the cancellation and dematerialization of physical share certificates for the quarter ended December 31, 2022. It is a formal attestation letter from the Registrar and Share Transfer Agent to the company and stock exchanges. The document is short (2937 characters) and primarily serves as a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or detailed financial data. It is not an announcement of a report but a certification under a specific regulation. Therefore, it fits best under Regulatory Filings (RNS), which covers officer certifications, attestations, and compliance documents that do not fit other categories.
2023-01-11 English
Credit Rating
Regulatory Filings Classification · 95% confidence The document is a notification to stock exchanges about a credit rating assigned to the company by a rating agency. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, which pertains to disclosure of material events. The content is an update on credit rating, not a financial report, audit, or earnings release. It is a regulatory announcement about credit rating changes, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories like Capital/Financing Update (CAP) or Interest Rate Update (IRAT). The document is short and informational, not a report or presentation.
2022-12-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.